Tag: Vaccine

The Drugs Controller General of India has given the Serum Institute of India a green light to conduct phase 2 and 3 human trials of the Oxford-AstraZeneca COVID-19 vaccine candidate in India..................

Serum Institute of India has been supported under the Department of Biotechnology’s National Biopharma Mission for conduct of a multisite randomized double-blinded placebo-controlled phase III clinical trial of a recombinant BCG vaccine candidate, VPM1002.............................

In order to accelerate research and development pertaining to COVID-19, the Review Committee on Genetic Manipulation (RCGM) functioning in DBT has processed/considered more than 100 applications till date, on a fast-track mode....................

Operation Warp Speed is part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.......................

Vaccine Discovery Programme supported by the Department of Biotechnology, Govt. of India under the National Biopharma Mission, implemented by BIRAC moves into clinical trials The study will assess the safety, tolerability and immunogenicity of the vaccine.................

On 14th July, 2020, Serum Institute of India, Pune has been granted permission to manufacture domestically developed first Pneumococcal Polysaccharide Conjugate Vaccine

The four-week placebo-controlled, blinded and randomized tests to be conducted in mice will seek to evaluate safety and examine immune response dose titration in the rodent model................

Human trials of India’s first indigenous experimental vaccine against COVID-19, COVAXIN, developed by Bharat Biotech is set to begin across India in July........................

Referring to Gavi, Prime Minister Narendra Modi while addressing the virtual Global Vaccine Summit said it is not just a global alliance but also a symbol of global solidarity and a reminder of that by helping others we can also help ourselves..............

The Coalition for Epidemic Preparedness Innovations (CEPI) will provide consortium comprising Bharat Biotech (BBIL) and the International Vaccine Institute (IVI) with up to US$14.1 million for vaccine manufacturing and clinical development of a two-dose live-inactivated vaccine (BBV87) against Chikungunya..............